NEW research presented overnight at the International Pharmaceutical Federation's Pharmaceutical Sciences World Congress in Stockholm has shown significant progress in a more effective cystic fibrosis treatment.
Scientists have developed a formulation that increases the delivery of a novel "antivirulence" agent to the lungs.
About 80% of CF patients suffer from chronic lung infections related to Pseudomonas aeruginosa which significantly increase morbidity.
The international group of researchers has been working on a new type of compound called quorum sensing inhibitors (QSIs) which can interrupt communication pathways between bacterial cells, resulting in reduced virulence and decreased tolerance to antibiotics.
The research presented at the congress shows that using certain solubilising excipients allows the product of a multidrug formulation that can deliver the desired amount of the QSI and tobramycin to the lungs of rats with P. aeruginosa infection.
The formulation was found to be effective in sensitising the bacteria to the antibiotic.
The above article was sent to subscribers in Pharmacy Daily's issue from 23 May 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 23 May 17
